内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Shattuck Labs, Inc.

STTK · Nasdaq · CIK 0001680367 · Healthcare · Biotechnology

内部人信号

当前没有活跃买入信号

1 qualifying P purchase group
当前 180 天评分窗口

18 同一窗口内观察到的 Form 4 交易行
6 sales · 11 期权、代扣税、授予、赠与或其他交易行

最近一次合资格买入2026-06-09 · SIEGALL CLAY B · $250.0K

为什么没有活跃信号？

买入活动存在
近期买入1 qualifying line group(s)
近期卖出中等
买入信号状态未激活
评分构成

活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。

Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算

为什么没有分数？

  • 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
  • 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。

卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
Shukla Abhinav A.Chief Technical Officer
○▼○○▼○▼○▼○
SIEGALL CLAY BDirector
○●
Stout StephenSee Remarks
○○
Pandite Arundathy N.Chief Medical Officer
▼▼
Neill Andrew RChief Financial Officer
○
Schreiber TaylorChief Executive Officer
○
● 买入▼ 卖出○ 其他

—

买方广度与集中度

合资格买方1
买入集中度100%最大买方： SIEGALL CLAY B · $250.0K
聚集买入 · 15天1 insider峰值活动： 2026-06-09–2026-06-09

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

暂无已记录的活跃信号快照

Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-06-09 · SIEGALL CLAY B.

近期 Form 4 活动

1买入
6卖出
19其他 Form 4 交易行
20SEC 申报 · 365天
买入1 qualifying P line(s) · 180 days
卖出6 sale line(s) · 仅供背景
其他11 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

该股票尚未获取市场背景。每日任务会轮转处理美国股票池。

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
10,947,042
上期报告
6,808,662
日均成交量
1,821,507
回补天数
6.0

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-06-09SIEGALL CLAY B买入 (P)Common Stock62,500USD 4.00USD 250,000SEC 申报 ↗
2025-08-25ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC买入 (P)Common Stock6,306,127USD 0.87USD 5,486,330SEC 申报 ↗
2025-08-25Ashiya Mona买入 (P)Common Stock6,306,127USD 0.87USD 5,486,330SEC 申报 ↗
2024-12-04Green Jeremy; Redmile Group, LLC买入 (P)Common Stock, par value $0.0001 per share133,371USD 1.25USD 166,714SEC 申报 ↗
2024-10-07Schreiber Taylor买入 (P)Common Stock36,500USD 1.21USD 44,165SEC 申报 ↗
2024-06-28Brous Tyler买入 (P)Common Stock3,000USD 3.90USD 11,700SEC 申报 ↗
2024-06-27Brous Tyler买入 (P)Common Stock5,416USD 3.89USD 21,068SEC 申报 ↗
2024-06-26Schreiber Taylor买入 (P)Common Stock14,400USD 3.47USD 49,968SEC 申报 ↗
2022-04-26Golumbeski George买入 (P)Common Stock28,330USD 3.63USD 102,838SEC 申报 ↗
2022-04-22Golumbeski George买入 (P)Common Stock234USD 3.67USD 859SEC 申报 ↗
2022-04-21Golumbeski George买入 (P)Common Stock26,049USD 3.69USD 96,121SEC 申报 ↗
2022-01-19Brous Tyler买入 (P)Common Stock3,000USD 6.87USD 20,610SEC 申报 ↗
2022-01-18Brous Tyler买入 (P)Common Stock2,500USD 7.01USD 17,525SEC 申报 ↗
2022-01-14Brous Tyler买入 (P)Common Stock2,500USD 7.16USD 17,900SEC 申报 ↗
2020-10-14Green Jeremy; Redmile Group, LLC买入 (P)Common Stock3,441,176USD 17.34USD 59,668,794SEC 申报 ↗

Form 4 申报证据

26 transaction lines in the latest 365-day window; 201 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-07-06Shukla Abhinav A.期权行权／转换 (M)Common Stock12,153USD 3.57USD 43,386SEC 申报 ↗
2026-07-02Shukla Abhinav A.卖出 (S)Common Stock410USD 7.01USD 2,874SEC 申报 ↗
2026-07-02Shukla Abhinav A.期权行权／转换 (M)Common Stock410USD 3.57USD 1,464SEC 申报 ↗
展开近期 Form 4 证据 (26 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-07-06Shukla Abhinav A.期权行权／转换 (M)Common Stock12,153USD 3.57USD 43,386SEC 申报 ↗
2026-07-02Shukla Abhinav A.卖出 (S)Common Stock410USD 7.01USD 2,874SEC 申报 ↗
2026-07-02Shukla Abhinav A.期权行权／转换 (M)Common Stock410USD 3.57USD 1,464SEC 申报 ↗
2026-07-01Shukla Abhinav A.卖出 (S)Common Stock100USD 7.07USD 707SEC 申报 ↗
2026-07-01Shukla Abhinav A.期权行权／转换 (M)Common Stock100USD 3.57USD 357SEC 申报 ↗
2026-06-30Shukla Abhinav A.卖出 (S)Common Stock23,365USD 7.08USD 165,424SEC 申报 ↗
2026-06-30Shukla Abhinav A.期权行权／转换 (M)Common Stock23,365USD 3.57USD 83,413SEC 申报 ↗
2026-06-30Pandite Arundathy N.卖出 (S)Common Stock30,000USD 7.01USD 210,300SEC 申报 ↗
2026-06-09SIEGALL CLAY B买入 (P)Common Stock62,500USD 4.00USD 250,000SEC 申报 ↗
2026-05-22SIEGALL CLAY B奖励／授予 (A)Common Stock128,054USD 1.08USD 138,298SEC 申报 ↗
2026-05-21Shukla Abhinav A.奖励／授予 (A)Common Stock5,122USD 1.08USD 5,532SEC 申报 ↗
2026-05-15Stout Stephen奖励／授予 (A)Common Stock12,805USD 1.08USD 13,829SEC 申报 ↗
2026-05-12Shukla Abhinav A.卖出 (S)Common Stock2,032USD 7.01USD 14,244SEC 申报 ↗
2026-05-12Shukla Abhinav A.期权行权／转换 (M)Common Stock2,032USD 3.57USD 7,254SEC 申报 ↗
2026-05-12Pandite Arundathy N.卖出 (S)Common Stock30,000USD 6.61USD 198,300SEC 申报 ↗
2026-05-12Neill Andrew R奖励／授予 (A)Common Stock64,027USD 1.08USD 69,149SEC 申报 ↗
2026-05-12Schreiber Taylor奖励／授予 (A)Common Stock25,610USD 1.08USD 27,659SEC 申报 ↗
2026-05-10Stout Stephen代扣税 (F)Common Stock968USD 6.85USD 6,631SEC 申报 ↗
2026-01-25Stout Stephen代扣税 (F)Common Stock593USD 4.15USD 2,461SEC 申报 ↗
2026-01-25Pandite Arundathy N.代扣税 (F)Common Stock3,195USD 4.15USD 13,259SEC 申报 ↗
2026-01-25Neill Andrew R代扣税 (F)Common Stock2,589USD 4.15USD 10,744SEC 申报 ↗
2026-01-25DeYoung Casi代扣税 (F)Common Stock2,286USD 4.15USD 9,487SEC 申报 ↗
2026-01-10Stout Stephen代扣税 (F)Common Stock4,153USD 4.75USD 19,727SEC 申报 ↗
2026-01-10Pandite Arundathy N.代扣税 (F)Common Stock6,851USD 4.75USD 32,542SEC 申报 ↗
2026-01-10Neill Andrew R代扣税 (F)Common Stock6,660USD 4.75USD 31,635SEC 申报 ↗
2026-01-10DeYoung Casi代扣税 (F)Common Stock5,699USD 4.75USD 27,070SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码STTK
CIK0001680367
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所Nasdaq

数据覆盖

本地 Form 4 历史201 transaction lines from 2020-10-14 to 2026-07-06
22 P purchase lines · 82 S sale lines · 97 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.